Medtronic plc's Stock Analysis

Medtronic Announces Executive Leadership Change in Neuroscience Division

Medtronic plc has announced that Brett Wall will leave his position as Executive Vice President and President of the Neuroscience Portfolio on May 18, 2026. Dr. Kweli Thompson, currently Senior Vice President and President of Cardiac Rhythm Management, will take over this role starting June 1, 2026.

Mr. Wall will continue to work with Medtronic until September 1, 2026, to facilitate a smooth transition. He is entitled to severance payments and benefits as per the company's established practices for executive officers, as detailed in the 2025 Proxy Statement filed with the Securities and Exchange Commission.

May 18, 2026 16:30:33

Medtronic Reports Unauthorized Access to IT Systems

Medtronic plc announced on April 24, 2026, that an unauthorized third party accessed data within certain corporate IT systems. The company has activated its incident response protocols and is collaborating with cybersecurity experts to investigate and remediate the situation. So far, there has been no identified impact on product safety, customer connections, manufacturing operations, or financial reporting systems. Medtronic reassures that its corporate IT networks are separate from hospital customer networks, which remain secure and managed by the customers' IT teams.

The company does not anticipate any material impact on its business or financial results due to this incident. Medtronic is actively working to identify any personal information that may have been accessed and will provide necessary notifications and support services as needed. The company emphasizes its commitment to patient safety and data security while taking steps to enhance system security in response to the incident.

Apr 24, 2026 17:45:33

Medtronic Announces FDA Clearance for MiniMed Flex Insulin Pump

Medtronic's subsidiary, MiniMed Group, Inc., received FDA clearance for the MiniMed Flex™, a smartphone-controlled insulin pump, ahead of schedule. This product is expected to enhance MiniMed's market presence and is part of a research and development agreement with Blackstone Life Sciences Advisors, which includes a royalty arrangement based on net sales. Medtronic will incur a one-time charge of $157 million in Q4 fiscal year 2026, impacting earnings per share by $0.08 due to its 90% ownership in MiniMed.

Following these developments, Medtronic revised its non-GAAP earnings per share guidance for fiscal year 2026 to a range of $5.50 to $5.54, down from a previous estimate of $5.62 to $5.66. Additionally, the initial public offering of 10% of MiniMed, expected to close on March 9, 2026, will result in a dilution effect of approximately $0.04 per share in the same quarter. The guidance for fiscal year 2027 remains unchanged, anticipating high single-digit EPS growth.

Mar 24, 2026 16:42:04

Medtronic Reports Q3 Fiscal 2026 Financial Results and Growth

Medtronic plc announced its third quarter fiscal year 2026 financial results, reporting a revenue of $9.0 billion, marking an increase of 8.7% as reported and 6.0% on an organic basis. The company's GAAP diluted earnings per share (EPS) stood at $0.89, while the non-GAAP diluted EPS was $1.36, exceeding the midpoint of the guidance. Significant growth was noted in the Cardiovascular portfolio, which rose 11% year-over-year, and the Cardiac Ablation Solutions segment saw an 80% increase, largely attributed to the success of its pulsed field ablation portfolio. Medtronic also received various regulatory approvals for its products, including the Hugo robotic-assisted surgery system and the Stealth AXiS Surgical System for spinal procedures.

The company's financial performance was bolstered by a strong showing in several segments, with Cardiovascular revenue increasing 13.8% and Diabetes revenue up 8.3%. Medtronic reiterated its fiscal year 2026 guidance for organic revenue growth of approximately 5.5% and a diluted non-GAAP EPS range of $5.62 to $5.66. The company emphasized its commitment to investing in research and development, as well as pursuing mergers and acquisitions to drive future growth, having completed two key transactions in the quarter.

Feb 17, 2026 06:48:07

Medtronic Reports Q2 Fiscal 2026 Revenue and EPS Growth

Medtronic plc announced its financial results for the second quarter of fiscal year 2026, reporting revenue of $9.0 billion, a 6.6% increase from the previous year. The company achieved a GAAP diluted EPS of $1.07 and a non-GAAP diluted EPS of $1.36, both reflecting an 8% increase. Notably, the Cardiac Ablation Solutions segment saw significant growth of 71%, driven by the pulsed field ablation portfolio. Medtronic received favorable coverage determinations for key procedures and secured FDA approvals for new devices, enhancing its market position.

The company raised its full-year fiscal 2026 guidance, projecting organic revenue growth of approximately 5.5% and adjusting its non-GAAP EPS forecast to a range of $5.62 to $5.66. This revision follows strong performance in the first half of the fiscal year, with robust procedure volumes and market demand contributing to overall growth. Medtronic's diverse portfolio, including advancements in cardiovascular, diabetes, and surgical technologies, positions it for continued momentum moving forward.

Nov 18, 2025 06:47:14

Medtronic Executive Vice President to Retire in December 2025

Gregory L. Smith, the Executive Vice President of Enterprise Operations at Medtronic plc, has announced his retirement effective December 2, 2025. Following his retirement, he will join a private equity-held organization.

Upon retirement, Mr. Smith will receive retirement treatment for his outstanding equity compensation. This includes the acceleration of unvested stock options and continued vesting of restricted stock units and performance stock units, as outlined in the company's previous filings.

Nov 03, 2025 17:21:46

Medtronic Shareholders Approve Key Amendments and Director Elections

Medtronic plc held its Annual General Meeting on October 16, 2025, where shareholders approved several important amendments to the Company's Articles of Association. These amendments included changes to authorize the Board of Directors to capitalize certain non-distributable reserves and updates to the advance notice provisions. The meeting also involved the election of twelve directors to serve until the 2026 Annual General Meeting and the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026.

In addition to the director elections and auditor ratification, shareholders approved various proposals including the renewal of the Board's authority to issue shares and opt out of pre-emption rights. The Company was also authorized to make overseas market purchases of its ordinary shares. A capital reduction was approved to create distributable reserves under Irish law. The meeting had a quorum with over 1.1 billion ordinary shares represented, ensuring that all votes were validly cast.

Oct 21, 2025 16:16:47

Medtronic Issues €1.49 Billion in Senior Notes Offering

Medtronic, Inc., a subsidiary of Medtronic plc, has issued €750 million in 2.950% Senior Notes due 2030 and €750 million in 4.200% Senior Notes due 2045. The offering is expected to generate net proceeds of approximately €1.49 billion, which will be used to repay existing senior notes maturing in 2025. The Notes are fully guaranteed by Medtronic Global Holdings S.C.A. and Medtronic plc, and have been approved for listing on the New York Stock Exchange.

The Notes will mature on October 15, 2030, and October 15, 2045, respectively, and will have general unsecured senior obligations ranking equally with other existing senior indebtedness. Medtronic, Inc. retains the option to redeem the Notes prior to their maturity under specified conditions. Additionally, the redemption of €500 million of existing senior notes due 2025 was executed on the same date as the issuance of the new Notes, contingent upon the successful completion of this offering.

Sep 29, 2025 08:45:28

Medtronic Announces Senior Notes Offering and Redemption Plan

On September 15, 2025, Medtronic plc announced the pricing of an offering to issue €750 million in 2.950% Senior Notes due 2030 and €750 million in 4.200% Senior Notes due 2045. The net proceeds from this offering are intended to be used to repay existing 0.000% and 2.625% Senior Notes due 2025. This financial activity is reflected in the company's fiscal year 2026 adjusted earnings per share guidance previously reiterated on August 19, 2025.

Additionally, Medtronic Luxco has elected to redeem all €500 million of its outstanding 2.625% Senior Notes due 2025 on September 29, 2025, contingent upon the completion of the new notes issuance. The redemption will occur at 100% of the principal amount plus accrued interest. Notice of this redemption will be communicated to registered holders by the Paying Agent, and further details can be obtained from them.

Sep 16, 2025 16:41:16

Medtronic Reports First Quarter Fiscal 2026 Financial Results

Medtronic plc announced its financial results for the first quarter of fiscal year 2026, reporting revenue of $8.6 billion, which represents an 8.4% increase compared to the previous year. The company achieved a GAAP diluted earnings per share (EPS) of $0.81, marking a 1% increase, while the non-GAAP diluted EPS rose by 2% to $1.26. The growth was driven by a nearly 50% increase in revenue from Cardiac Ablation Solutions, particularly in the U.S., alongside solid performances in other key product categories including Neuromodulation and Diabetes. Medtronic reiterated its guidance for organic revenue growth of approximately 5% for the fiscal year and raised its diluted non-GAAP EPS guidance to a range of $5.60 to $5.66, up from the previous range of $5.50 to $5.60.

Additionally, Medtronic's Board of Directors expanded from 11 to 13 members, appointing John Groetelaars and William Jellison as new directors. Both will serve on the newly formed Growth committee, with Jellison also joining the Operations committee. Their appointments are part of the company's ongoing efforts to enhance governance and drive growth. The company is focused on accelerating revenue growth in the second half of the fiscal year while increasing investments in research and development, sales, and marketing to foster long-term shareholder value.

Aug 19, 2025 06:49:43